The California Horse Racing Commission issued the following advice on September 23 on the CHRB 1867 rule, issued by CHRB executive Scott Chaney to CHRB licensed veterinarians:
The California Horse Racing Board (CHRB) wishes to reaffirm its interpretation of Rule 1867, subsection (b). In particular, subsection (b) prohibits, “The possession and/or use on the premises of an establishment under the jurisdiction of the Board of Directors of any drug, substance, or pharmaceutical product that has not been approved by the United States Food and Drug Administration (FDA) approved for use in the United States.” The combination drug is not approved by the FDA.
The CHRB’s longstanding interpretation of subsection (b) is that legally prescribed combination drugs manufactured according to Federal and State guidelines do not violate this regulation. The CHRB recognizes that combination drugs are needed for safe and effective treatment of horses. These medications contain substances approved by the Federal Food and Drug Administration (FDA), which have been combined to achieve the appropriate dosages for safe and effective horse treatment and are essential to the physician’s needs. equine veterinarian to effectively treat various medical conditions. Using the combination drug in the manner described does not violate the CHRB regulations.
Permit the use of sublabelled drugs for therapeutic purposes, based on diagnosis and VCPR, in equine patients through AMDUCA1. The CHRB regulation permits such use where FDA-approved drugs do not exist — a situation that often occurs in equine practice.
If there are specific questions regarding compliance with Rule 1867, veterinarians are encouraged to contact an Official Veterinarian prior to administration.
This press release has not been edited by BloodHorse. If you have any questions, please contact the organization that produced the release.